8-K: PharmaCyte Biotech Executes 1-for-19 Reverse Stock Split

PharmaCyte Biotech, Inc. has completed a 1-for-19 reverse stock split to increase its per-share trading price and comply with Nasdaq listing requirements.

Summary

• PharmaCyte Biotech, Inc. has implemented a 1-for-19 reverse stock split, effective November 12, 2026.
• This action was taken to increase the per-share trading price of its common stock and regain compliance with The Nasdaq Capital Market's minimum bid price requirement.
• The reverse stock split was approved by stockholders on March 30, 2026, and became legally effective on November 12, 2026, with trading on a split-adjusted basis commencing November 13, 2026.
• The company's common stock will continue to trade under the ticker symbol PMCB.
• Approximately 10,755,649 shares outstanding as of November 11, 2026, will be reduced to approximately 566,087 shares post-split.
• Fractional shares will be settled in cash, calculated based on the closing price on November 12, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as a reverse stock split is often a sign of a company struggling to maintain compliance with exchange listing requirements, indicating underlying financial or market valuation challenges.

Positives

• The reverse stock split aims to help the company regain compliance with Nasdaq's minimum bid price requirement, potentially avoiding delisting.
• The total authorized number of shares remains unchanged, preserving flexibility for future capital needs.

Negatives

• A reverse stock split is often a signal of a company's struggle to maintain its stock price, which can be viewed negatively by investors.
• The need for a reverse split suggests potential underlying issues with the company's financial performance or market perception.
• Fractional shares will be paid out in cash, which could result in a small cash payout for some shareholders.

Risks

• Failure to maintain compliance with Nasdaq's minimum bid price requirement could lead to delisting.
• The reverse stock split may not be sufficient to address the underlying business challenges that led to the low stock price.
• Market perception of reverse stock splits can be negative, potentially impacting investor confidence and future stock performance.

Future Outlook

The company's immediate future outlook is focused on maintaining compliance with Nasdaq listing requirements following the reverse stock split. The effectiveness of this measure in achieving sustained compliance and improving market perception remains to be seen.

Management Comments

• The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often viewed negatively, corporate action within the biotechnology sector, particularly for smaller companies struggling with market capitalization and exchange listing requirements. Competitors facing similar pressures may also consider such measures.

Stakeholder Impact

• Shareholders will hold fewer shares, but the total value of their holdings should remain proportionally the same immediately after the split, subject to market fluctuations and cash payments for fractional shares.
• The company's ability to attract and retain investors may be influenced by the perception of the reverse stock split.
• Creditors and other stakeholders may view the reverse split as a sign of financial distress, potentially impacting their confidence in the company's long-term viability.

Next Steps

• Monitor the company's stock price to ensure continued compliance with Nasdaq's minimum bid price requirement.
• Observe market reaction to the reverse stock split and its impact on investor sentiment.
• Evaluate the company's ability to execute its business strategy and achieve financial milestones post-split.

Key Dates

Recommendation

A hold recommendation is advised as the reverse stock split is a procedural move to maintain exchange listing rather than a fundamental improvement in the company's business prospects. While it addresses an immediate compliance issue, it does not inherently change the company's underlying financial health or growth trajectory. Investors should await further developments regarding the company's operational progress and financial performance before considering a buy or sell decision.

Keywords

Reverse Stock Split, Nasdaq Compliance, Stock Price, Shareholder Value, Capital Markets, Corporate Action, Biotechnology